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Abstract
 
The MC148 CC chemokine from the human poxvirus molluscum contagiosum (MCV) was
probed in parallel with viral macrophage inflammatory protein (vMIP)-II encoded by human
herpesvirus 8 (HHV8) in 16 classified human chemokine receptors. In competition binding
using radiolabeled endogenous chemokines as well as radiolabeled MC148, MC148 bound
with high affinity only to CCR8. In calcium mobilization assays, MC148 had no effect on its
own on any of the chemokine receptors, but in a dose-dependent manner blocked the stimula-
tory effect of the endogenous I-309 chemokine on CCR8 without affecting chemokine-
induced signaling of any other receptor. In contrast, vMIP-II acted as an antagonist on 10 of
the 16 chemokine receptors, covering all four classes: XCR, CCR, CXCR, and CX
 
3
 
CR.
In chemotaxis assays, MC148 specifically blocked the I-309–induced response but, for exam-
ple, not stromal cell–derived factor 1
 
a
 
, monocyte chemoattractant protein 1, or interleukin
8–induced chemotaxis. We thus concluded that the two viruses choose two different ways to
block the chemokine system: HHV8 encodes the broad-spectrum chemokine antagonist
vMIP-II, whereas MCV encodes a highly selective CCR8 antagonist, MC148, conceivably to
interfere with monocyte invasion and dendritic cell function. Because of its pharmacological
selectivity, the MC148 protein could be a useful tool in the delineation of the role played by
CCR8 and its endogenous ligand, I-309.
Key words: monocytes • Kaposi sarcoma–associated herpesvirus • dendritic cells • 
chemokines • chemokine receptors
 
Introduction
 
The poxvirus molluscum contagiosum (MCV)
 
1
 
 causes small
benign tumors in the skin of immunocompetent children
and opportunistic infections in immunocompromised pa-
tients. MCV lesions are characterized by a surprising ab-
sence of surrounding inflammatory cell infiltrates (1–3). The
genome of MCV contains several genes corresponding to
human genes suggested to take part in immune evasion, such
as a homologue of the MHC, a protein with identity to the
human peroxidase, and finally an open reading frame (ORF),
 
MC148R
 
, which codes for a chemokine-like protein that,
based on its sequence, was originally suggested to be a
chemokine antagonist (4).
Chemokines are 70–80-amino acid proteins with well
characterized three-dimensional structures usually stabilized
by two disulfide bridges. They are involved in attracting
and activating distinct leukocyte subsets, for example to in-
flammatory foci and specific tissues and microenvironments
within tissues, as in a lymph node (5–7). The precise num-
ber of human chemokines is still unclear but is likely to be
 
z
 
45–55. They are divided into four families on the basis of
the pattern of the conserved cysteine residues located near
their NH
 
2
 
 terminus and forming disulfide bridges with cys-
teines located further COOH-terminally in the molecule.
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 HEK, human embryonic kidney; HHV,
human herpesvirus; MCP, monocyte chemoattractant protein; MCV,
molluscum contagiosum virus; ORF, open reading frame; RANTES,
regulated upon activation, normal T cell expressed and secreted; SDF,
stromal cell–derived factor; vMIP, viral macrophage inflammatory protein. 
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In the CC family, the two NH
 
2
 
-terminal cysteines are adja-
cent; in the CXC family, the two residues are separated by
a single amino acid; and in the CX
 
3
 
C family, the separation
is by three amino acids. The XC family, which as yet has
only one member, has just one cysteine near the NH
 
2
 
 ter-
minus. Chemokines exert their function through seven-trans-
membrane (7TM), G protein–coupled receptors, of which
today nine are CC chemokine receptors, five are CXC
chemokine receptors, one is a CX
 
3
 
C chemokine receptor,
and one is an XC chemokine receptor. On the basis on
their function, chemokine receptors can be classified in an
“inflammatory group,” which is activated under patholog-
ical conditions, and a “housekeeping group,” taking care of
re-circulation and maturation of lymphocytes in the un-
challenged host (5).
In the last couple of years, it has become clear that sev-
eral herpes- and poxviruses code for chemokine proteins
and/or chemokine-like 7TM receptors (8–12). Viral 7TM
receptors are encoded by CMV (13, 14), human herpesvi-
rus (HHV)6 (15, 16), HHV7 (17), and HHV8 (18). In ad-
dition to this, EBV as well as HHV6 and HHV7 have been
shown to upregulate certain endogenous chemokine recep-
tors in their target cells. Thus, EBV actively upregulates the
expression of endogenous CCR7, previously called EBV-
induced molecule (EBI) 1, as well as an orphant receptor,
EBI 2, in infected B cell lines (19), whereas HHV6 and
HHV7 actively upregulate CCR7 in infected CD4
 
1
 
 T cells
(20). As CCR7 is believed to be a receptor that mediates
migration of cells to lymph nodes, this could be a way that
the virus obtains tissue targeting to secondary lymphoid tis-
sues, i.e., by “telling the infected cell” where it would like
to go by upregulating or expressing a suitable chemokine
receptor. However, for most of the receptors encoded by
the virus itself, a function has not yet been identified, ex-
cept in the case of the ORF-74 receptor from HHV8, which
apparently functions as a virally encoded oncogene due to
its high constitutive signaling activity (18, 21, 22), and the
US28 receptor from CMV, which appears to be involved
in the cellular transfer of virus (23).
As for the receptors, only some of the virally encoded
chemokine proteins have been characterized pharmacolog-
ically. Thus, CMV encodes an uncharacterized CXC chemo-
kine as well as a newly characterized CXCR2 agonist (24,
25), whereas HHV6 encodes a uncharacterized CC chemo-
kine (15, 26). Regarding HHV8, functions for two of the
three chemokines encoded by the virus have been suggested.
The first is viral macrophage inflammatory protein (vMIP)-
II, which has been shown to be a surprisingly broad-spec-
trum antagonist for both CC and CXC chemokine recep-
tors in vitro
 
 
 
(27). In accordance with this finding, vMIP-II
was shown to function as an efficient immunosuppressive
agent in vivo, i.e., in a rat model for glomerulonephritis (28).
Very recently, it was demonstrated that vMIP-I, also from
HHV8, could act not as a blocker but as a selective agonist
for CCR8 (29, 30). Interestingly, it has also been shown that
vMIP-II, which otherwise is a broad-spectrum chemokine
antagonist, in fact can act selectively as a chemoattractant
for eosinophils (31).
In this study, we characterize the binding and function
of the MCV-encoded chemokine MC148 in parallel with
the broad-spectrum chemokine antagonist vMIP-II from
HHV8. Previously, it had been suggested that MC148,
analogous to vMIP-II, could also be a broad-spectrum an-
tagonist (32). However, we report here that MC148 binds
very selectively to CCR8 and blocks the function of only
this receptor without affecting the function of any other
chemokine receptor tested. Thus, the viral protein can be a
very useful immunological tool due to its high selectivity
for this particular receptor. Furthermore, the selective tar-
geting of CCR8 by the virus also indicates that this recep-
tor could be an interesting drug target.
 
Materials and Methods
 
Chemokines.
 
I-309 and murine lymphotactin were purchased
from R & D Systems, Inc., and thymus-expressed chemokine was
purchased from PeproTech, Inc. IL-8 and MIP-1
 
a 
 
were expressed
in 
 
Escherichia coli
 
 and purified in our facilities. Fractalkine, liver-
activated and -regulated chemokine, MCP-1, MCP-3, RANTES
(regulated upon activation, normal T cell expressed and secreted),
and vMIP-II were provided by Tim Wells (Ares-Serono, S.A.
Geneva, Switzerland). Macrophage-derived chemokine and second-
ary lymphoid tissue chemokine were provided by Thomas Schall
(ChemoCentryx, San Carlos, CA). I-TAC (IFN-inducible T cell
 
a
 
 chemoattractant) was provided by Kuldeep Neote (Pfizer, Inc.,
Groton, CT). Stromal cell–derived factor (SDF)-1
 
a
 
 was provided
by Michael Luther (Glaxo-Wellcome, Research Triangle Park,
NC). B cell–attracting chemokine 1 was provided by Bernhard
Moser (Thedor-Kocher Institute, Bern, Switzerland).
 
Stable Cell Lines.
 
The Chinese hamster ovary (CHO) cells sta-
bly expressing CCR1, CCR2, CCR3, CCR5, CXCR1, CXCR2,
and CXCR4, as well as human embryonic kidney (HEK)293
cells stably expressing CCR6 and CCR8, were provided by Tim
Wells (Serono, Geneva, Switzerland). L12 cells stably expressing
CCR4, XCR1, and CX
 
3
 
CR1 were a gift from Osamu Yoshie
(Kinki University, Osaka, Japan). Kuldeep Neote (Pfizer, Inc., Gro-
ton, CT) provided 300.19 cells expressing CXCR3, and Bernhard
Moser (Thedor-Kocher Institute, Bern, Switzerland) provided
300.19 cells expressing CXCR5. Gabriel Marquez (Autonomous
University, Madrid, Spain) provided HEK293 cells stably express-
ing CCR9. L1.2 cell lines expressing CCR7 and CCR8 were es-
tablished at ICOS Corp. (Johnny Stine).
 
Isolation of PBLs and PMNs.
 
To purify PBLs, whole blood
from healthy donors was diluted 1:1 in PBS and centrifuged on
Histopaque
 
®
 
 (Sigma Chemical Co.). PBMCs were collected from
the interface and were washed twice in PBS. The cells were further
purified by negative selection with anti-CD14 magnetic beads
(Miltenyi Biotec) to remove monocytes. PMNs were isolated by
centrifugation on a 7.4% Ficoll, 15.5% Hypaque solution (Sigma
Chemical Co.). The PMN layer was collected, and the cells were
washed twice in PBS before resuspension in chemotaxis buffer.
 
Cloning of the Gene.
 
A biopsy was taken from an MCV ele-
ment from a 9-yr-old child, and a QIAamp tissue kit (QIAGEN
Inc.) was used to extract total DNA. Based on the nucleotide
sequence deposited in EMBL/GenBank/DDBJ (available under
accession no. U60315), the MC148R gene was amplified by
PCR. The full-length coding sequence was inserted in the pTEJ
vector, which uses the Ubiquitin UbC promotor (33). Nucleo-
tide sequence analysis was performed on an ABI 377 sequence
system (Perkin-Elmer Corp.). 
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Production of Recombinant Protein.
 
COS-7 cells were transiently
transfected by a calcium phosphate precipitate method with addi-
tion of chloroquine. Serum-free medium was collected 24, 48,
and 72 h after transfection. The medium was centrifuged at 1,500 
 
g
 
for 20 min, and the supernatant was adjusted to pH 4.5 and fil-
tered through 0.22-
 
m
 
m filters (Nalgene). The medium was di-
luted with water 1:1 to decrease ionic strength and loaded on cat-
ion exchange SP-Sepharose columns (Pharmacia Biotech). The
columns were washed with 50 mM sodium acetate buffer, pH
4.5, and the protein was eluted with 2 M NaCl in the same
buffer. The eluate was made 0.2% in TFA, filtered, and loaded on
a C8 column (Vydac) for reverse-phase HPLC, from which the
protein was eluted with 0.1% TFA in water on a gradient of
CH
 
3
 
CN. The elution position of the recombinant MC148 pro-
tein as well as the purity was identified with mass spectroscopy
and NH
 
2
 
-terminal sequence analysis on an ABI 494 protein se-
quencer (Perkin-Elmer Corp.). The identity of each subsequent
batch was identified with mass spectroscopy. The yield was 
 
z
 
4–6
 
m
 
g/175 cm
 
2
 
 flask per harvest.
 
Cell Binding.
 
Whole cell binding (0.8–2.5 
 
3 
 
10
 
5 
 
cells per
well) was performed at 4
 
8
 
C for 3 h in 0.5 ml of 25 mM Hepes
buffer containing 1 mM CaCl
 
2
 
 and 5 mM MgCl
 
2
 
, at pH 7.2,
supplemented with 0.5% BSA on transiently transfected COS-7
cells. The incubation was stopped by washing four times with 0.5 ml
of ice cold binding buffer made 0.5 mM in NaCl. Cell-associated
radioactivity was determined after extraction of the cells with 8 M
urea in 3 M acetic acid supplemented with 1% NP-40. Nonspe-
cific binding, determined in the presence of the relevant chemo-
kine peptide (0.1 
 
m
 
M), was subtracted. The following radio-
actively labeled peptides were from Amersham: 
 
125
 
I–MIP-1
 
a
 
(IM285), 
 
125
 
I–MCP-1 (IM280), 
 
125
 
I–RANTES (IM288), 
 
125
 
I–I-
309 (IM313), and 
 
125
 
I–IL-8 (IM249). 
 
125
 
I–metSDF-1
 
a
 
, 
 
125
 
I–frac-
talkine, and 
 
125
 
I–MC148R were prepared in our facilities, the
first two by oxidative iodination and the latter by Bolton-Hunter
iodination before HPLC purification.
 
Calcium Fluorimetry.
 
Cells stably transfected with various chemo-
kine receptors were loaded with Fura-2AM (Molecular Probes,
Inc.) in a Krebs ringer buffer, pH 7.4 (CHO and HEK293 stable
transfectants) or RPMI with 1% FCS (L12 and 300.19 stable
transfectants) for 20–30 min. Aliquots were made of 10
 
6
 
 cells, and
each aliquot was pelleted and resuspended in 500 
 
m
 
l of Krebs
ringer buffer or RPMI (depending on cell type) with 10 mM
EGTA. Fluorescence was measured on a Jobin Yvon FlouroMax-2
(Jobin Yvon Spex) as the ratio of emission at 490 nm when excited
at 340 and 380 nm, respectively.
 
In Vitro Chemotaxis.
 
Chemotaxis was measured using 24 trans-
wells polycarbonate membranes (3 
 
m
 
m; Corning Costar Corp.).
Chemokines were diluted in 0.6 ml chemotaxis buffer (RPMI
containing 0.5% BSA) and added to the lower chemotaxis cham-
ber. 10
 
6
 
 PMNs, PBLs, or L1.2/CCR8 cells or 0.75 
 
3 
 
10
 
6
 
 THP-1
cells were resuspended in 0.1 ml chemotaxis buffer and added to
the top chamber insert. Chemotaxis plates were then incubated
for 30 min (PMN) or 4 h (PBL, THP-1, or L1.2/CCR8) at 37
 
8
 
C
in a 5% CO
 
2
 
-humidified incubator. After the incubation, the
cells from the bottom well were collected and counted by
FACS
 
®
 
 (Becton Dickinson).
 
Results
 
Cloning and Expression of the MC148R Gene.
 
The MC148R
gene was cloned from a skin lesion of a patient, and se-
quence analysis showed that it was identical to the gene
from the MCV subtype 1 (deposited in EMBL/GenBank/
DDBJ under accession no. U60315). COS-7 cells were
used for production of the MC148 chemokine protein,
which was collected in conditioned, serum-free medium,
subjected to cation exchange chromatography followed by
HPLC purification. Production of the viral chemokine in
the eukaryotic cells should secure that the protein product
corresponds to the chemokine normally secreted from cells
infected by the virus. The conditioned medium contained
a major protein peak eluting at 35% acetonitrile that corre-
sponded to the processed, secreted MC148 protein (Fig. 1).
Mass spectroscopy and NH
 
2
 
-terminal sequence analysis re-
vealed a single protein with a molecular mass of 8,984 dal-
tons and a cleavage site for the secretory signal peptide be-
tween residues 24 and 25 of the precursor protein (Fig. 2).
The HPLC-purified MC148 protein was used for receptor
activation studies, in chemotaxis assays, and, after being ra-
dioactively labeled with 
 
125
 
I and HPLC purified, in recep-
tor binding studies.
 
Receptor Binding Studies.
 
To characterize the binding pro-
file of MC148, we probed a panel of human chemokine
receptors in both heterologous and homologous binding
experiments. MC148 was not able to compete for binding
against the radioactively labeled human chemokines used as
radioligands for CCR1, CCR2, CCR5, CXCR1, CXCR2,
CXCR4, and CX
 
3
 
CR1 (Fig. 3). However, MC148 did dis-
place 
 
125
 
I–I-309 from CCR8 transiently expressed in COS-7
cells with subnanomolar affinity (IC
 
50
 
 
 
5 
 
0.47 nM; 95% CI;
0.33–0.67 nM). The affinity of the MC148 protein corre-
sponds to that of the endogenous CCR8 ligand I-309 (IC
 
50
 
 
 
5
 
0.52 nM), but interestingly, 
 
z
 
20% of the bound 
 
125
 
I–I-309
could apparently not be displaced by the viral protein (Fig.
Figure 1. Purification of recombinant MC148 expressed in COS cells.
The elution profile of MC148 (black box) on reverse-phase HPLC is
shown. mAU, milliabsorbance units. 
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3). vMIP-II from HHV8 also bound to CCR8, albeit with
a somewhat lower affinity (IC
 
50
 
 
 
5 
 
27.8 nM; Fig. 3).
Heterologous competition binding experiments can
sometimes be misleading, as a high-affinity ligand may not
always be able to compete for binding against another
high-affinity ligand (34). Direct binding experiments using
 
125
 
I–MC148 confirmed the high-affinity binding of the vi-
ral protein to human CCR8 (IC
 
50
 
 
 
5
 
 0.27 nM; 95% CI;
0.24–0.30 nM) and demonstrated the suitability of the radio-
active peptide as a radioligand in receptor binding experi-
ments. Nevertheless, 
 
125
 
I–MC148 was unable to bind spe-
cifically to any other human chemokine receptor tested
(CCR1, CCR2, CCR5, CXCR1, CXCR2, CXCR4, and
CX
 
3
 
CR1; Fig. 3). In all these cases, binding experiments
were performed in parallel with the appropriate radioac-
tive, endogenous chemokine to confirm suitable receptor
expression (Fig. 3). Thus, both heterologous and homolo-
gous binding experiments indicate that the MC148 chemo-
kine from MCV is a selective CCR8 ligand.
 
Calcium Mobilization Studies.
 
Calcium mobilization was
studied in 16 cell lines individually expressing 16 different
human chemokine receptors. As shown in Fig. 4, in each
Figure 2. Alignment of known CCR8 ligands to MC148. vMIP-II, vMIP-I, MC148, and I-309 were aligned using CLUSTALW 1.7. Identical
amino acids are shown white on black, whereas similar amino acids are shown white on gray. The line above the alignment shows the secondary struc-
ture of vMIP-II as determined by NMR (51). *Cysteine residues.
Figure 3. Heterologous and homologous competition binding experiments with recombinant MC148 with various chemokine receptors. Heterolo-
gous competition binding curves for MC148 are shown to the left; human chemokine corresponding to the radioactively labeled human chemokine used
(j), MC148 (n), and vMIP-II (s). Homologous binding curves for MC148 are shown to the right; MC148 (m), I-309 (u), and vMIP-II (s). For ev-
ery homologous binding experiment with 125I–MC148, a homologous control curve was made with the human chemokine known to bind the receptor
to make sure that the receptor was expressed on the surface of the cell. 
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Figure 4. Effect of recombinant MC148 and vMIP-II on calcium mobilization on a panel of cell lines stably transfected with humane chemokine recep-
tors. 1027 M MC148, vMIP-II, or vehicle was added to the cells at 50 s, followed by a submaximal dose of an appropriate endogenous human chemokine
at 150 s. The height of the response with the endogenous ligand was measured, and the heights in the experiments with MC148 and vMIP-II were ex-
pressed as percent of the height in the experiment with the vehicle. A representative example of each experiment is shown to the left, whereas the box di-
agram to the right shows the average inhibition with SEM as indicated. Asterisks (*) indicate statistically significant inhibition (P , 0.05). The chemokine
concentrations used were: CCR1, 10210 M RANTES; CCR2, 1028 M MCP-1; CCR3, 1029 M MCP-3; CCR4, 1029 M macrophage-derived chemo-
kine; CCR5, 1029 M RANTES; CCR6, 1028 M liver-activated and -regulated chemokine; CCR7, 1029 M secondary lymphoid tissue chemokine;
CCR8, 1028.5 M I-309; CCR9, 1027 M thymus-expressed chemokine; CXCR1, 1029 M IL-8; CXCR2, 1029 M IL-8; CXCR3, 10210 M I-TAC;
CXCR4, 10210 M SDF-1a; CXCR5, 10210 M B cell–attracting chemokine 1; XCR1, 1027 M murine lymphotactin; and CX3CR1, 1029 M fractalkine.176 MC148, a Highly Selective CCR8 Antagonist
cell line the appropriate, endogenous human chemokine
was able to rapidly increase intracellular calcium concentra-
tions. In contrast, MC148 given at 1027 M concentration
had no effect on calcium mobilization in any of the cell
lines (Fig. 4). More importantly, pretreatment with 1027 M
MC148 did not diminish the response to the appropriate
endogenous chemokine elicited through any of the tested
human chemokine receptors, except for CCR8 (Fig. 4). In
the HEK293 cells expressing CCR8, pretreatment with
MC148 in a dose-dependent manner and with an IC50 of
7.1 nM blocked the calcium response to I-309 (Fig. 5).
Despite the observation that MC148 in binding experi-
ments was unable to compete for binding against 20% of
the bound 125I–I-309, the viral chemokine totally blocked
the calcium response elicited by I-309 through CCR8.
In contrast to MC148, vMIP-II acted as a broad-spec-
trum antagonist, as it inhibited the receptor-mediated cal-
cium mobilization in 10 out of 16 human chemokine recep-
tors tested. As previously reported, vMIP-II fully blocked
the ligand-induced calcium mobilization through CCR1,
CCR2, CCR5, and CXCR4 and partially blocked the
CCR3-mediated response, whereas the CXCR1-mediated
calcium flux was unaffected (27). Interestingly, the antago-
nistic repertoire of vMIP-II was here extended to also cover
the two minor families of chemokines, fractalkine and lym-
photactin, as it totally blocked the calcium responses in-
duced by these chemokines through CX3CR1 and XCR1,
respectively (Fig. 4). Finally, it was found that vMIP-II
could partially block CCR4, CCR8, and CXCR3. In con-
trast, vMIP-II had no effect on the calcium responses elic-
ited by the appropriate endogenous chemokine through
CCR6, CCR7, CCR9, CXCR2, and CXCR5.
Thus, as studied in cells individually expressing the vari-
ous cloned receptors and in respect of signal transduction
through calcium mobilization, vMIP-II from HHV8 truly
is a broad-spectrum chemokine antagonist covering recep-
tors for all four families of chemokines, whereas MC148
from MCV acts as a highly selective CCR8 antagonist.
Effect on Chemotaxis. The potential chemotactic activ-
ity of MC148 was tested on freshly isolated and purified
neutrophils, PBLs, and THP-1 cells, as well as on L1.2 cells
transfected with CCR8. When administered alone, MC148
was not able to chemoattract any of these cell types. MC148
was also unable to inhibit SDF-1–induced chemotactic re-
sponse of PBLs (Fig. 6), conceivably mediated through
CXCR4, which is in agreement with the lack of effect of
MC148 on the SDF-1–induced calcium mobilization.
MC148 did not affect the IL-8–induced chemotactic re-
sponse of neutrophils or the MCP-1–induced response of
THP-1 cells, which is in agreement with the lack of effect
of MC148 on cloned CXCR2 and CCR2, respectively.
However, as expected based on the effect on signal trans-
duction, MC148 did block the I-309–induced chemotactic
response on L1.2 cells transfected with CCR8 (Fig. 6). It is
noteworthy that MC148 inhibited CCR8-mediated chemo-
taxis in a concentration similar to the concentration of
I-309 used to chemoattract the cells. Furthermore, we tested
the chemotactic activity of vMIP-II on CCR8-transfected
L12 cells. vMIP-II was unable to chemoattract any of the
cell types tested; it did block the I-309–mediated chemo-
Figure 5. Dose–response curve of recombinant MC148 on I-309–
induced calcium mobilization in stably CCR8-transfected HEK293 cells.
1027, 1028, 1029, and 10210 M MC148 or vehicle was added to the cells
at 50 s, followed by 1028.5 M I-309 at 150 s. The height of the response
with I-309 was measured, and the heights in the experiments with the
different concentrations of MC148 were expressed as percent of the
height in the experiment with the vehicle. A representative example is
shown to the left; the box diagram to the right shows the average inhibi-
tion with SEM as indicated.
Figure 6. Effect of MC148 on chemotactic activity on THP-1 cells
(monocytic cell line), PBLs, neutrophils, and CCR8-transfected L12
cells. To the left, dose–response curves for MC148 (n). Dose–response
curves (h) for MCP-1, SDF-1a, IL-8, and I-309 are shown for compari-
son. The bottom panel includes a dose–response curve for vMIP-II (s).
To the right, dose–response curves for inhibition by MC148 (m) of
chemotaxis induced by 5 nM MCP-1 on THP-1 cells, 10 nM SDF-1a
on PBLs, 10 nM IL-8 on neutrophils, and 10 nM I-309 on CCR8-trans-
fected L12 cells. The bottom panel includes a dose–response curve for in-
hibition by vMIP-II (d). One representative assay out of three is shown
for THP-1 cells, out of four for PBLs, out of three for neutrophils, and
out of five for CCR8-transfected L12 cells.177 Lüttichau et al.
taxis, but at concentrations z100-fold higher than the ef-
fective concentration of I-309.
Discussion
Through a systematic analysis using 16 cloned and cate-
gorized human chemokine receptors, we find here that the
MC148 chemokine from MCV is a highly specific ligand
for CCR8 and that it specifically blocks the binding and
action of the endogenous ligand I-309 on this receptor. In
contrast, another virally encoded chemokine, vMIP-II from
HHV8, is found to be an even more broad-spectrum
chemokine antagonist than originally described (27), as it
bound and blocked 10 out of 16 chemokine receptors tested,
covering all four classes of chemokine receptors. Thus, the
two viruses, MCV and HHV8, have apparently exploited
two different avenues to interfere with the chemokine branch
of the immune system of their host. The fact that MCV
specifically addresses CCR8 is interesting and points to this
receptor as playing a key role in our immune system. This
also suggests that CCR8 could be a useful drug target as well.
MC148 Is a Surprisingly Selective Chemokine Antagonist.
MC148 was discovered only recently as an ORF during the
sequencing of the genome of MCV and, based on its de-
duced amino acid sequence, it was then suggested that it
might function as a chemokine antagonist (4). This notion
was supported by the short NH2-terminal extension of the
virally encoded chemokine and the observation that several
endogenous CC chemokines become antagonists by modi-
fication or shortening of their NH2 termini (35–38). It is
interesting that the two extra cysteine residues of MC148,
which very likely could form a third intramolecular disul-
fide bridge, are found in the COOH-terminal end of the
molecule. However, the possible structural and functional
consequences of these two cysteine residues are still unclear
and remain to be determined experimentally. When the
MC148 protein was subsequently expressed and tested, it
was found to act, as expected, as a chemokine antagonist
(32, 39). However, in contrast to the findings in our study,
MC148 was in the first reports described as a broad-spec-
trum chemokine antagonist based on its apparent ability to
block the chemotactic response of several types of chemo-
kines (32). Nevertheless, very little data was presented in
these preliminary reports on the effect of MC148 on indi-
vidual, cloned chemokine receptors except for CCR8. We
cannot explain why it was originally found that the MC148
protein could inhibit the chemotaxis induced by various
chemokines, as the protein product apparently was identi-
cal, although the protein in our study was produced by ex-
pression in COS-7 cells from an artificial eukaryotic ex-
pression plasmid and in the previous study was produced in
HeLa/BS-C-1 cells after infection with recombinant vac-
cinia virus (32). Nevertheless, it should be noted that in both
studies it was found that MC148 acts potently as an antago-
nist on CCR8. We would like to emphasize that the selec-
tive action of MC148 on CCR8 in our report is supported
by the parallel characterization of vMIP-II as a truly broad-
spectrum antagonist. Moreover, the double HPLC-puri-
fied, radioactively labeled MC148 protein also bound with
high affinity only to CCR8.
Why Does MCV Specifically Block CCR8? Unfortunately,
this important question cannot be answered well in this re-
port due to the limited information available concerning
both CCR8 as such and its specific ligand, I-309. CCR8
has been found on the surfaces of monocytes (40), and I-309
has been to shown to be a chemoattractant for monocytes
(41), whereas Th2 cells have been shown to upregulate
CCR8 transcripts as well as respond with an intracellular
I-309–mediated calcium flux upon activation (42, 43). Fur-
thermore, I-309 has been shown to be produced by acti-
vated T cells (44) and IL-1–stimulated monocytes (45), as
well as by an activated human mast cell line. MCV lesions
are characterized by an absence of inflammatory cell infil-
trate (1, 2) as well as the absence of Langerhans cells, the
APCs of the epidermis (2, 3). Monocytes have been shown
to be precursors of Langerhans cells (47) as well as antigen-
presenting dendritic cells (48). Thus, it could be speculated
that MCV has optimized MC148 to block CCR8-medi-
ated recruitment of monocytes, resulting in a lack of APCs
that creates a stalemate between the virus and the host in
which the host cannot eliminate the virus and the virus
cannot disseminate. It should also be noted that MCV does
code for proteins other than MC148, which also could be
involved in interfering with the host immune response (4).
The question posed above can in fact be turned around.
The fact that the virus has taken the effort to carefully opti-
mize the MC148 chemokine to be such a selective, high-
affinity antagonist for CCR8 indicates that this as yet
poorly characterized receptor probably plays an important
role in our immune system. Importantly, with MC148, the
virus at the same time has provided a highly useful pharma-
cological tool for delineating the function of CCR8 and its
endogenous ligand, I-309.
vMIP-II Is an Even More Broad-Spectrum Chemokine Antag-
onist than Expected. Originally, we found that vMIP-II
could block CCR1, CCR2, CCR5, and the CMV-encoded
US28, as well as the CXC chemokine receptor CXCR4
(27). Subsequently, vMIP-II has also been reported to block
CX3CR1 and CCR8, as well as the HHV8-encoded
chemokine receptor ORF-74 (22, 28, 30, 49). Here we find
that vMIP-II also can antagonize CCR4, CXCR3, and
XCR1. Thus, vMIP-II is able to bind and block receptors
for all known classes of chemokines: XCR, CX3CR, CCR,
and CXCR. Endogenous chemokines, in contrast to many
other chemical messengers, are often able to bind to more
than one receptor type. However, even the most “promis-
cuous” endogenous chemokines do not cross-react with re-
ceptors outside of their own class. For example, RANTES
binds to CCR1, CCR3, and CCR5, and IL-8 binds to
CXCR1 and CXCR2. In contrast, HHV8 has during its
efficient evolution and in vivo selection been able to opti-
mize vMIP-II to exploit not only one but all four classes of
chemokine receptors. The receptors not targeted by vMIP-II
appear to be the neutrophil-activating ones, that is CXCR1
and CXCR2, and those with housekeeping functions,
CCR7, CCR9, CXCR5, and CCR6.178 MC148, a Highly Selective CCR8 Antagonist
However, the function of vMIP-II may be dependent
on the cellular setting, as it has been reported under certain
circumstances to be able to act as a chemoattractant for
certain cells, i.e., eosinophils—conceivably acting through
CCR3—and even for CCR8-transfected Jurkat cells (31,
49, 50). It should be noted that in both cases these are re-
ceptors for which vMIP-II does not appear to be a particu-
larly high-affinity ligand (Fig. 4). Nevertheless, the func-
tion of vMIP-II as a general chemokine antagonist has been
supported by an in vivo study, where vMIP-II was used in
a rat kidney inflammatory disease model. Here, vMIP-II
given intravenously was able to act as a potent and efficient
immunosuppressive agent (28). It will be interesting to see
if vMIP-II and especially the poxvirus-encoded, selective
CCR8 antagonist MC148 can function as immunosuppres-
sive agents in other disease models.
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